Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab and/or Dazodalibep in Highly Sensitized Kidney Transplant Candidates
NCT04174677Phase 2Withdrawn
- Sponsor
- Amgen
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of inebilizumab, dazodalibep in end stage renal disease (ESRD), sponsored by Amgen. Planned start Dec 2019; status: withdrawn.
02
Drugs
inebilizumabdazodalibep
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT04174677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174677.